- About Us
- Our Research
- Diseases and conditions
- Research Groups
- Research support and facilities
- Aboriginal and Torres Strait Islander Health
- Participate in our research
- Research highlights
- Research history
- Glossary of research terms
- Support Us
- Why support QIMR Berghofer?
- Ways to help
- Book a tour or guest speaker
- Christmas Appeal
- Our supporters
- Thanks to our donors
- News & Events
- Contact Us
- Our Services
- CMV study
- Queensland Pancreatic Cancer Study
- QIMR Berghofer Centre for Immunotherapy and Vaccine Development
|Share on Facebook||Share on Twitter||Share on LinkedIn|
Study overviewPancreatic cancer is the 10th most commonly occurring cancer in most western countries, but is the fourth leading cause of cancer death. This year, 2,000 Australians will be diagnosed with pancreatic cancer and about the same number will die of this disease. Despite the impact of pancreatic cancer, knowledge about its causes is limited. In particular, there have been few efforts to examine interactions between genetic and environmental factors.
To increase understanding about pancreatic cancer it is essential to conduct a study that is large enough to evaluate gene-environment interactions. This improved knowledge may lead to targeted preventive measures and to improved treatment.
ObjectiveTo establish an integrated, multidisciplinary approach to the study of pancreatic cancer by collecting epidemiological and clinical data and biological samples from a large population-based group of people diagnosed with pancreatic cancer and a comparable group of population controls. This process will result in a biorepository linked to a comprehensive epidemiological, molecular and clinical database for future studies.
QPCS is the first large Australian population-based study of pancreatic cancer. It is population-based study, where patients are identified through a network of treating clinicians and through the Queensland Cancer Registry. Controls are being sampled from the Commonwealth Electoral Roll, matched on age and sex to the patients.
This study will provide a better understanding of the causes of pancreatic cancer and will potentially lead to developing preventive strategies for high-risk populations. The information from the study will be a resource that can be used to discover diagnostic markers and predict the effectiveness of therapies.